logo-loader

Genflow Biosciences says it has made 'excellent strategic' progress since float

Published: 03:09 16 May 2022 EDT

Genflow Biosciences PLC -

Genflow Biosciences PLC (LSE:GENF) said it had made excellent strategic progress since its float in January.

It said its pre-clinical programmes remain on track with human trials expected to get underway in around two years.

In the period since the IPO, the group, which focuses on treatments for healthy long life, signed a scientific research collaboration with the University of Rochester's Aging Research Center.

The pair will research the potential of Sirtuin-6 in reversing the ageing process in liver tissue, which, the company said, is the “first step towards a true rejuvenation gene therapy across a range of tissues”.

It also inked a similar tie-up with Organips, a French biotechnology company and world leader in cellular ageing reversibility.

The research will focus on the potential of the Sirtuin-6 gene variant found in people aged more than 100 years old in reversing the ageing process in certain cells.

The update also provided an insight into Genflow’s finances. It showed that as at May 13, the group had £3.6mln in the bank, or around two-and-a-half years’ working capital.

"I am delighted with the excellent strategic progress that Genflow has delivered since our landmark IPO to become Europe's first listed pure-play longevity company,” said Dr Eric Leire, founder and chief executive of Genflow.

“The company's senior leadership have a strategy in place to advance our pre-clinical research programmes, which remain on track.”
 

Genflow Biosciences says new research grants validate its research into...

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire joins Proactive's Stephen Gunnion with details of two significant research grants in Belgium. The grants, aimed at fostering collaborations in advanced therapy medicinal products (ATMPs), notably support partnerships with EXO...

on 01/24/2024